MBRX

Moleculin Biotech, Inc.
CAPPED RATING

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech, Inc. (MBRX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
B+
Factor Score 3.8 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
F
Factor Score 0.5 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -34.1%
Price Return 12M -32.7%
Catalyst Signal 0.00
Market Cap $8.2M
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.8) D+ (1.8) F (0.5) D (1.3) C+ (2.6) C- (2.0)
2026-11-06 B+ (3.8) D+ (1.8) F (0.5) C- (2.1) C+ (2.7) C (2.2)
2026-10-30 A- (3.9) D+ (1.8) F (0.5) C- (2.1) C+ (2.7) C (2.2)
2026-10-23 B+ (3.7) C- (1.9) F (0.5) C- (1.9) C+ (2.6) C- (2.1)
2026-10-16 B+ (3.7) D+ (1.8) F (0.5) F (0.4) C+ (2.6) D+ (1.8)
Page 1 of 3